ClinicalTrials.gg
RecruitingNCT05828459Updated Mar 20, 2025

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

A Phase 1 interventional study of OT-A201 and IMids in Hematological Malignancy and Solid Tumor, sponsored by Onward Therapeutics. Recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Onward Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 142 studies in Hematologic Neoplasms with a site in France — 49 open to participants now, 58 under way, 5 of them phase 3. Hematologic Neoplasms · France.

Planned enrollment
40th of 107
150 · median 106
Started
2023
with 7 others
Phase 1
18 of 142
4 open now
Primary completion
2027-01
later than 20 of 57 live
Registered
113th of 142
by date

Among the 142 studies in Hematologic Neoplasms with a site in France, this one is the 40th largest by planned enrollment of the 107 interventional ones that give a count, is one of 8 that started in 2023, is one of 18 in phase 1, reaches primary completion later than 20 of the 57 other live ones, and was the 113th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

49 of the 142 studies in Hematologic Neoplasms with a site in France are open now. Recruiting first, the newest first:

43 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Hematologic Neoplasms with a site in France, or all of them as a file.
02

Study summary

This phase 1 study is aimed at establishing the safety basis of OT-A201 in the treatment of hematological malignancies and solid tumors. In the dose of escalation part it is to characterize the overall safety and tolerability profile and determine the recommended dose(s) of OT-A201 as monotherapy, and in various combination regimens. Preliminary information about anti-cancer activity will be further explored in the expansion part of the study.

03

Conditions studied

  • Hematological Malignancy
  • Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • or cytologically confirmed hematological or advanced/ solid cancer
  • Have had all available therapeutic standards for their disease
  • Willingness to undergo baseline /bone marrow aspiration in case biopsy was not collected after completion of the most recent prior therapy
  • performance status ≤ 1
  • > 3 months as assessed by the investigator
  • Acceptable clinical lab results

Main Exclusion Criteria:

  • Systemic at a daily dose of > 10 mg of prednisone or equivalent within 28 days before study treatment. Transient use of steroids for other medical condition may be allowed
  • Ongoing immune-related adverse events irAEs and or AEs ≥ grade 2 from previous therapies not resolved except vitiligo, stable neuropathy up to grade 2, hair loss, and stable endocrinopathies with substitutive hormone therapy
  • Within 4 weeks of major surgery
  • Documented history of active disorder requiring systemic therapy within the last 12 months
  • Prior solid organ transplant
  • Primary or secondary immune deficiency
  • Active and uncontrolled infection requiring intravenous antibiotic or antiviral treatment
  • Seropositive (except after vaccination or confirmed cure for hepatitis) for (HIV), virus (HBV), or virus (HCV)
  • disease
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    OT-A201 monotherapy

    OT-A201 administered by IV infusion on a weekly (qw) basis. An alternative dosing schedule of every 2 weeks (q2w) may be implemented based on the clinical safety and laboratory data.

    Drug: OT-A201

  • Experimental
    OT-A201 in combination with iMiD

    OT-A201 in combination with lenalidomide or pomalidomide at the approved dose

    Drug: OT-A201 · Drug: IMids

  • Experimental
    OT-A201 in combination with a specific agent

    OT-A201 in combination with late stage approved treatment (combination to be defined by a protocol amendment)

    Drug: OT-A201 · Drug: TBD Compound

  • Experimental
    OT-A201 in combination with bevacizumab

    OT-A201 in combination with bevacizumab at the approved dose

    Drug: OT-A201 · Drug: Bevacizumab

  • Experimental
    OT-A201 in combination with paclitaxel

    OT-A201 in combination with paclitaxel at the approved dose

    Drug: OT-A201 · Drug: Paclitaxel

Interventions

  • DrugOT-A201

    OT-A201 IV infusion qw or q2w

  • DrugImmunomodulating AgentsStudies of Immunomodulating AgentsImmunomodulating Agents pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle

    Also known as: lenalidomide, pomalidomide

  • Combination regimen for solid tumor Bevacizumab: 10 mg/m² q2w

  • Combination regimen for solid tumor Paclitaxel: 175 mg/m² q3w

  • DrugTBD Compound

    Combination regimen for hematological malignancy

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose(s) (MTD) and recommended dose(s) of OT-A201

    Evaluate dose-limiting toxicity (DLT) during the DLT observation period

    Time frame: 28 days

  2. Safety profile of OT-A201

    Incidence, severity, and relationship of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs leading to discontinuation of study treatment; and clinically significant findings on clinical laboratory tests, vital signs, ECGs, and physical examinations

    Time frame: 6 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jan 2027, 42 months after the start.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 42 months is close to that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
Apr 25, 2023
StartActual
Jul 10, 2023
Primary completionEst.
Jan 2027
CompletionEst.
Jul 2027
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05828459
Lead sponsor
Onward Therapeutics
Responsible party
Sponsor
First posted
Apr 25, 2023
Start date
Jul 10, 2023
Primary completion
Jan 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Mar 20, 2025

Study contacts

Bruno Piccolella
Contact
bruno.piccolella@onward-therapeutics.com
+33 6 12 97 73 68
Erica Wang
Contact
erica.wang@onward-therapeutics.com
+886 921 865 855
Eric Raymond, MD, PhD
principal investigator · Saint-Joseph Hospital - Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion